Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03855137 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 778
- Enrollment target
NCT03855137: Completed Phase 3 study, sponsored by Allergan.
NCT03855137 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 778 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03855137, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 778 participants
- Enrollment target
Study Summary
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
Primary Outcome
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Ne
Interventions
- DRUG Placebo
- DRUG Atogepant 60 mg
- DRUG Atogepant 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 778 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 3 |
What the finished NCT03855137 record still lists
NCT03855137 is an interventional study that assigns participants to a tested intervention. The registered 778 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03855137 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03855137 about?
NCT03855137 is a clinical study titled "Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine". This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
What is the current status of trial NCT03855137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 778 participants. The study started on 2019-03-11. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT03855137?
The interventions under investigation include: Placebo (DRUG), Atogepant 60 mg (DRUG), Atogepant 30 mg (DRUG).
Who is sponsoring clinical trial NCT03855137?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03855137's enrollment target sits among peer trials
778 438th of 2000 higher than 1,563 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06841679 · 778 participants · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI